Acute Ischaemic Stroke
Acute Ischaemic Stroke
Search
Survodutide Phase III study weight loss
Boehringer Ingelheim to advance survodutide into three global Phase III studies in obesity
CHMP_opinion_nintedanib_ILD_PF
Nintedanib received a CHMP positive opinion for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
New indications NexGard, NexGard SPECTRA and Broadline
New therapeutic indications for NexGard®, NexGard SPECTRA® and Broadline® approved by EMA
Stargardt Disease
Stargardt Disease is a hereditary condition which causes degeneration of cells in the retina at the back of the eye.
Raising Questions or Concerns
Supplier must report ethics and compliance concerns that might affect Boehringer Ingelheim.
Innovation in medicinal chemistry
Darryl McConnell, Research Site Head, Austria and Jürgen Mack, Medicinal Chemistry, explain how we are working to unlock unsolved diseases
The Boehringer Ingelheim Veterinary Scholars Program
The aim of the Boehringer Ingelheim Veterinary Scholars Program is to expose students to biomedical research
“Rare diseases are quite common”
Rare diseases are individually rare but collectively affect millions of people worldwide. Yet, they remain under-researched and are often misdiagnosed.
CHMP recommends new treatment for chronic kidney disease
The CHMP of EMA has granted a positive opinion recommending empagliflozin for the treatment of adults with chronic kidney disease
empulse-trial-benefit-acute-heart-failure
Empagliflozin provided a significant clinical benefit in adults stabilized in hospital following acute heart failure in EMPULSE Phase III trial
preserved-heart-failure-treatment-approval-europe
preserved-heart-failure-treatment-approval-europe
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
founding-member-of-QUTAC
Together, the members of this newly founded consortium want to explore industrial applications for quantum computing
Martin Stefanic
Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
Mental health: a $1 trillion burden demanding policy action
Nearly one billion people around the world live with a mental health condition, yet an estimated 70% don’t have access to the help they need.
real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
EC_approval_nintedanib_ILD_PF
European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
CAROLINA-CARMELINA-Asia-analysis
CAROLINA® and CARMELINA® outcome trial subgroup analyses demonstrate cardiovascular and renal safety data in Asian adults with type 2 diabetes
Geographic Atrophy
Geographic atrophy (GA) is an advanced and severe form of dry age-related macular degeneration (AMD) that progresses slowly but can lead to permanent vision loss.
Respimat media
Diabetic macular edema and diabetic macular ischemia
Diabetic macular edema and diabetic macular ischemia are complications of diabetic retinopathy.
Iclepertin: GlyT1 inhibitor
Iclepertin: GlyT1 inhibitor
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis
cat feline diabetes medication treatment fda approval
Boehringer Ingelheim receives FDA approval for SENVELGO®